Dopamine D3 receptor (DRD3) Ser9Gly polymorphism may affect treatment response to antipsychotic drugs (APDs) in patients with schizophrenia, particularly those with the Ser allele and Ser/Ser genotypes. This was the result of a recent meta-analysis published in Neuroscience Letters.

Because past studies on the association have yielded inconsistent results, the researchers conducted a new meta-analysis to see if they could uncover more precise results. They searched PubMed, Cochrane Library, Medline, Embase, CNKI, Weipu, and Wanfang databases for eligible studies through March 2022. They included 13 studies with 1769 total patients.

Researchers found Ser9Gly polymorphism was significantly associated with treatment response to APDs in patients with schizophrenia in an allele model (Ser vs Gly, OR=0.72, 95% CI=0.58-0.89, P =.002), a recessive model (Ser/Ser vs Ser/Gly+Gly/Gly, OR=0.55, 95% CI=0.36-0.86, P =.008) and a co-dominant model (Ser/Ser vs Gly/Gly, OR=0.57, 95% CI=0.33-0.99, P =.045) in White individuals, but not in Asian individuals.


Continue Reading

Of the limitations, researchers only detected dichotomous outcomes. They did not collect specific scores from diagnostic scales. Also, they could not evaluate an association between Dopamine D3 receptor (DRD3) Ser9Gly polymorphism and specific APDs.

“In summary, this meta-analysis indicated that the DRD3 Ser9Gly may influence the efficacy of APDs in specific genetic models, of which Ser allele and Ser/Ser genotype contributed to poor clinical response in Caucasians,” said researchers. “Given the limitations of included studies in the meta-analysis, further well-designed studies with larger sample size are warranted to validate our results.”

Reference

Liu C, Xu X, Liu X, Zhang T, Li Y, Yan P. DRD3 Ser9Gly polymorphism and treatment response to antipsychotics in schizophrenia: a meta-analysis. Neurosci Lett. 2022;786:136788. doi:10.1016/j.neulet.2022.136788

This article originally appeared on Psychiatry Advisor